L. Pizzuti et al. / Ultrasonics Sonochemistry 17 (2010) 34–37
35
MeOH/H2O 1:1 (ꢀ0.5 mg/ml) were introduced into the source at
5 ml/min via an infusion pump (Cole-Parmer, Vernon Hills, IL,
USA). Nitrogen gas was used for nebulising (2 bar) and drying
(4 l/min, 160 °C). An accurate-mass calibration was obtained using
a solution of sodium trifluoroacetate (10 mg/ml) as internal stan-
dard. NMR spectra were recorded on a Bruker DPX 300 spectrom-
eter (300.13 MHz for 1H and 75.48 MHz for 13C) at 300 K.
The reactions were carried out with a microtip probe connected
to a 500 Watt Sonics Vibracell ultrasonic processor operating at
20 kHz at 25% of the maximum power output. The progress of reac-
tions was monitored on a Thermo Trace GC Ultra chromatograph,
Column I.D., 0.25 mm; Column length, 30 m; Column Head Pres-
sure, 14 psi.
167 °C; 1H NMR (300 MHz; DMSO-d6): d (ppm) 2.92 (dd, 1H,
JAB = 17.6 Hz, JAX = 5.2 Hz, HA), 3.79 (dd, 1H, JAB = 17.6 Hz,
JBX = 12.0 Hz, HB), 3.83 (s, 3H, OCH3), 5.67 (dd, 1H, JBX = 12.0 Hz,
JAX = 5.2 Hz, HX), 6.84–7.74 (m, 9H, aromatic H); 13C NMR
(75 MHz; DMSO-d6): d (ppm) 41.5 (C-4), 55.4 (OCH3), 55.9 (C-5),
111.1, 120.1, 125.3, 126.0, 128.1, 128.4, 129.1, 130.1, 131.7, 149.4
(12C, Ar), 154.2 (C-3), 155.6 (C(NH)NH2).
5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-
carboximidamide (2d): (0.47 g, 80%) C17H18N4O, 294.35, 147–
149 °C; 1H NMR (300 MHz; DMSO-d6): d (ppm) 3.06 (dd, 1H,
JAB = 17.6 Hz, JAX = 5.8 Hz, HA), 3.71 (s, 3H, OCH3), 3.78 (dd, 1H,
JAB = 17.7 Hz, JBX = 12.1 Hz, HB), 5.43 (dd, 1H, JBX = 12.0 Hz,
JAX = 5.8 Hz, HX), 6.85–7.75 (m, 9H, aromatic H); 13C NMR
(75 MHz; DMSO-d6): d (ppm) 42.7 (C-4), 54.9 (OCH3), 60.2 (C-5),
113.8, 125.9, 126.7, 128.4, 129.0, 131.8, 135.4, 148.2 (12C, Ar),
154.5 (C-3), 158.2 (C(NH)NH2).
2.2. Classical synthesis of 3,5-diaryl-4,5-dihydro-1H-pyrazole-1-
carboximidamides (2)
5-(4-Chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carb-
oximidamide (2e): (0.58 g, 98%) C16H15ClN4, 298.77, 163–165 °C;
1H NMR (300 MHz; DMSO-d6): d (ppm) 3.04 (dd, 1H, JAB = 17.7 Hz,
JAX = 5.9 Hz, HA), 3.82 (dd, 1H, JAB = 17.7 Hz, JBX = 12.2 Hz, HB), 5.50
(dd, 1H, JBX = 12.1 Hz, JAX = 5.8 Hz, HX), 7.20–7.75 (m, 9H, aromatic
H); 13C NMR (75 MHz; DMSO-d6): d (ppm) 42.4 (C-4), 60.1 (C-5),
126.0, 127.5, 128.3, 128.5, 129.2, 131.3, 131.6, 142.4 (12C, Ar),
148.6 (C-3), 154.5 (C(NH)NH2).
5-(2-Bromophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carb-
oximidamide (2f): (0.68 g, 99%) C16H15BrN4, 343.22, 168–170 °C;
1H NMR (300 MHz; DMSO-d6): d (ppm) 2.92 (dd, 1H, JAB = 17.7 Hz,
JAX = 5.8 Hz, HA), 3.91 (dd, 1H, JAB = 17.7 Hz, JBX = 12.3 Hz, HB), 5.68
(dd, 1H, JBX = 12.2 Hz, JAX = 5.8 Hz, HX), 7.06–7.74 (m, 9H, aromatic
H); 13C NMR (75 MHz; DMSO-d6): d (ppm) 41.3 (C-4), 60.5 (C-5),
120.8, 126.0, 126.4, 127.8, 128.4, 128.7, 129.1, 131.6, 132.6, 141.8
(12C, Ar), 148.4 (C-3), 154.3 (C(NH)NH2).
A mixture of chalcone 1 (2.0 mmol), aminoguanidine hydro-
chloride (4.0 mmol, 0.44 g) and KOH (4.0 mmol, 0.22 g) in ethanol
(10 ml) was stirred at reflux. After the time indicated (Table 1), the
reaction was allowed to cool, the excess of aminoguanidine hydro-
chloride was removed by filtration in a Büchner funnel and the eth-
anol was evaporated under reduced pressure. The solid residue
was dissolved in water (20 ml) and the product was extracted in
ethyl acetate (3 Â 20 ml). The organic extracts were combined,
dried (MgSO4) and the solvent removed under reduced pressure.
The product 2 obtained was purified by recrystallization from hex-
ane/EtOAc (1:1).
2.3. Ultrasound-promoted synthesis of 3,5-diaryl-4,5-dihydro-1H-
pyrazole-1-carboximidamides (2)
5-(4-Bromophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carb-
oximidamide (2g): (0.55 g, 80%) C16H15BrN4, 343.22, 136–138 °C;
1H NMR (300 MHz; DMSO-d6): d (ppm) 3.08 (dd, 1H, JAB = 17.8 Hz,
JAX = 5.5 Hz, HA), 3.85 (dd, 1H, JAB = 17.8 Hz, JBX = 12.1 Hz, HB), 5.52
(dd, 1H, JBX = 12.0 Hz, JAX = 5.5 Hz, HX), 7.15–7.77 (m, 9H, aromatic
H); 13C NMR (75 MHz; DMSO-d6): d (ppm) 42.5 (C-4), 60.1 (C-5),
120.0, 126.2, 127.8, 128.5, 129.4, 131.3, 131.4, 142.3 (12C, Ar),
149.7 (C-3), 154.2 (C(NH)NH2).
5-(3,4-Dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-
1-carboximidamide (2h): (0.64 g, 99%) C18H20N4O2, 324.38, 146–
148 °C; 1H NMR (300 MHz; DMSO-d6): d (ppm) 3.08 (dd, 1H,
JAB = 17.7 Hz, JAX = 5.8 Hz, HA), 3.71 (s, 3H, OCH3), 3.72 (s, 3H,
OCH3), 3.81 (dd, 1H, JAB = 17.7 Hz, JBX = 12.0 Hz, HB), 5.44 (dd, 1H,
JBX = 11.9 Hz, JAX = 5.8 Hz, HX), 6.70–7.77 (m, 8H, aromatic H); 13C
NMR (75 MHz; DMSO-d6): d (ppm) 42.9 (C-4), 55.4 (OCH3), 55.5
(OCH3), 60.6 (C-5), 109.2, 111.9, 117.3, 126.1, 128.5, 129.3, 131.6,
135.4, 147.8, 149.4 (12C, Ar), 148.7 (C-3), 154.4 (C(NH)NH2).
5-(2,4-Dichlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-
carboximidamide (2i): (0.58 g, 87%) C16H14Cl2N4, 333.22, 94–96 °C;
1H NMR (300 MHz; DMSO-d6): d (ppm) 2.99 (dd, 1H, JAB = 17.7 Hz,
JAX = 6.1 Hz, HA), 3.91 (dd, 1H, JAB = 17.7 Hz, JBX = 12.3 Hz, HB), 5.69
(dd, 1H, JBX = 12.3 Hz, JAX = 6.0 Hz, HX), 7.08–7.75 (m, 8H, aromatic
H); 13C NMR (75 MHz; DMSO-d6): d (ppm) 40.9 (C-4), 58.1 (C-5),
126.1, 127.4, 127.9, 128.5, 128.8, 129.3, 131.4, 131.6, 139.4 (12C,
Ar), 149.0 (C-3), 154.3 (C(NH)NH2).
A mixture of chalcone 1 (2.0 mmol), aminoguanidine hydro-
chloride (4.0 mmol, 0.44 g) and KOH (4.0 mmol, 0.22 g) in ethanol
(10 ml) was irradiated in an ultrasound probe at 25–30 °C for the
appropriate time (see Table 1). After filtration in a Büchner funnel,
to remove the excess of the aminoguanidine hydrochloride, the
ethanol was evaporated under reduced pressure. The solid residue
was dissolved in water (20 ml) and the product was extracted in
ethyl acetate (3 Â 20 ml). The organic extracts were combined,
dried (MgSO4) and the solvent removed under reduced pressure.
Finally, the 3,5-diaryl-4,5-dihydro-1H-pyrazole-1-carboximida-
mides were obtained in excellent purity.
2.4. Data spectra of products 2a-j
3,5-Diphenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide (2a):
(0.40 g, 75%) C16H16N4, 264.33, 167–169 °C; 1H NMR (300 MHz;
DMSO-d6): d (ppm) 3.05 (dd, 1H, JAB = 17.7 Hz, JAX = 5.6 Hz, HA),
3.84 (dd, 1H, JAB = 17.7 Hz, JBX = 12.1 Hz, HB), 5.53 (dd, 1H,
JBX = 12.0 Hz, JAX = 5.5 Hz, HX), 7.20–7.77 (m, 10H, aromatic H);
13C NMR (75 MHz; DMSO-d6): d (ppm) 42.8 (C-4), 60.6 (C-5),
125.4, 126.1, 126.9, 128.4, 128.5, 129.2, 131.6, 143.1 (12C, Ar),
149.1 (C-3), 154.3 (C(NH)NH2).
5-(2-Methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-car-
boximidamide (2b): (0.42 g, 75%) C17H18N4, 278.35, 188–190 °C;
1H NMR (300 MHz; DMSO-d6): d (ppm) 2.38 (s, 3H, CH3), 2.91
(dd, 1H, JAB = 17.6 Hz, JAX = 5.8 Hz, HA), 3.87 (dd, 1H, JAB = 17.6 Hz,
JBX = 12.2 Hz, HB), 5.61 (dd, 1H, JBX = 12.2 Hz, JAX = 5.8 Hz, HX),
6.95–7.75 (m, 9H, aromatic H); 13C NMR (75 MHz; DMSO-d6): d
(ppm) 18.9 (CH3), 41.5 (C-4), 58.0 (C-5), 124.1, 125.9, 125.9,
126.6, 128.5, 129.1, 130.3, 131.8, 133.9, 141.2 (12C, Ar), 148.5 (C-
3), 154.4 (C(NH)NH2).
3-Phenyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-
1-carboximidamide (2j): (0.64 g, 90%) C19H22N4O3, 354.40, 179–
181 °C; 1H NMR (300 MHz; DMSO-d6): d (ppm) 3.09 (dd, 1H,
JAB = 17.7 Hz, JAX = 6.5 Hz, HA), 3.63 (s, 3H, OCH3), 3.73 (s, 6H,
OCH3), 3.81 (dd, 1H, JAB = 17.7 Hz, JBX = 12.2 Hz, HB), 5.41 (dd, 1H,
JBX = 12.0 Hz, JAX = 6.5 Hz, HX), 6.53–7.76 (m, 7H, aromatic H); 13C
NMR (75 MHz; DMSO-d6): d (ppm) 42.8 (C-4), 55.7 (2 OCH3),
59.8 (OCH3), 61.1 (C-5), 102.6, 126.1, 128.5, 129.2, 131.7, 136.3,
139.0, 152.9 (12C, Ar), 149.0 (C-3), 154.8 (C(NH)NH2).
5-(2-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-
carboximidamide (2c): (0.58 g, 98%) C17H18N4O, 294.35, 165–